Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cixutumumab Plus Temsirolimus in Metastatic CRPC
NCT01026623Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Oct 2009
- Primary completion
- Feb 2013
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cixutumumab in metastatic castration-resistant prostate cancer (mCRPC), sponsored by National Cancer Institute. Primary endpoints: Composite Time to Progression, Tumor Response Rate and 1 more. Started Oct 2009; status: completed.
02
Drugs
cixutumumab
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT01026623.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01026623.